Trial Profile
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Jul 2023
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AMPLITUDE-L
- Sponsors Sanofi
- 20 Jul 2023 Results from three phase 3 studies: AMPLITUDE-D, AMPLITUDE-S, and AMPLITUDE-L reporting efficacy and safety data published in the Diabetes, Obesity and Metabolism
- 06 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 17 Nov 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2020.